Alzheimer’s disease, which accounts for 60-70% of dementia cases worldwide, may soon be treatable. The newest experimental drug, lecanemab, developed by pharmaceutical companies Eisai and Biogen, was found to slow down cognitive decline by 27% in a 18-months large scale clinical trial. 
About 1800 patients aged 50-90 years old with early stage Alzheimer’s Disease participated in the trial. Singapore’s National University Hospital (NUH) is one of the participating sites of the trial, and is the only one in South-east Asia. Caregivers interviewed were grateful that their loved ones were more jovial and social after receiving the lecanemab treatment. 
These results have reignited hope in the scientific community. There have been many false hopes and controversies in the two decade long research of finding a treatment for a disease with no known cure. Lecanemab may be the real deal, marking what could be ‘the beginning of the end’ for the disease.

Join our mailing list

Stay updated on all the latest news and events

Mr Ho Swee Huat

Mr Ho Swee Huat is the Founder and Managing Director of Abacus Assets Advisors Pte Ltd. Before starting the company, he had an established career in the banking industry, with 20 years of experience in Singapore, Hong Kong and New York.

He was an Independent Director and Chairman of the Audit Committee of CapitaCommercial Trust Management LTD from 2004 to 2013.

He is the current Chairman of Autism Association (Singapore) which he co-founded with a group of parents in 1992. He is also Vice-Chairman of Eden School, a special school for children with autism.

Mr Ho holds a Master’s degree from the London School of Economics and Political Science, and a Liberal Arts degree in Economics from Hamilton College, USA.

He has been a member of the Board of the Foundation since its incorporation.